 |
|
Imatinib mesylate-induced interstitial lung disease in a patient with prior history of Mycobacterium tuberculosis infection
Na-Ri Lee, Ji Won Jang, Hee Sun Kim, Ho-Young Yhim
Korean J Intern Med. 2015;30(4):550-553. Published online 2015 Jun 29 DOI: https://doi.org/10.3904/kjim.2015.30.4.550
|
|
Citations to this article as recorded by
 Treatment dilemmas in patients with gastrointestinal stromal tumors (GIST) who experienced imatinib-induced pneumonitis: A case series
Deborah van de Wal, Evelyne Roets, Roos F. Bleckman, Jorn Nützinger, Birthe C. Heeres, J. Martijn Kerst, Mahmoud Mohammadi, Anna K.L. Reyners, Ingrid M.E. Desar, Astrid W. Oosten, Neeltje Steeghs, Winette T.A. van der Graaf
Current Problems in Cancer: Case Reports.2024; 13: 100280. CrossRef Hypersensitivity pneumonitis related to imatinib mesylate therapy in a patient with chronic myeloid leukemia
Faten Kallel, Olfa Kassar, Imen Maaloul, Maha Charfi, Kamilia Ksouda, Moez Elloumi
Journal of Oncology Pharmacy Practice.2021; 27(7): 1762. CrossRef Effects of host‐directed therapies on the pathology of tuberculosis
Liana Tsenova, Amit Singhal
The Journal of Pathology.2020; 250(5): 636. CrossRef Imatinib-induced irreversible interstitial lung disease
Ping Zhang, Jingfeng Huang, Fangfang Jin, Jiaohai Pan, Guifang Ouyang
Medicine.2019; 98(8): e14402. CrossRef Update on the management of chronic myeloid leukemia: current best practice and future directions
Aisling Nee, Jeffrey H. Lipton
Expert Opinion on Orphan Drugs.2019; 7(4): 157. CrossRef Association between infection and severe drug adverse reactions: an analysis using data from the Japanese Adverse Drug Event Report database
Takuya Imatoh, Kimie Sai, Chisato Fukazawa, Yasushi Hinomura, Ryosuke Nakamura, Yoshimi Okamoto-Uchida, Katsunori Segawa, Yoshiro Saito
European Journal of Clinical Pharmacology.2017; 73(12): 1643. CrossRef Imatinib
Reactions Weekly.2015; 1564(1): 104. CrossRef
|